Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells

Journal of International Medical Research

Volumn 40, Issue 2, 2012, Pages 426-435

  Li, Q ^a   Sui, H ^a   Fan, Z Z ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

ABCB1; Cancer; Multiple drug resistance (MDR); P glycoprotein; Signal transduction pathway

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE C; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA;

ABCB1 GENE; ARTICLE; CANCER CELL CULTURE; GENE; GENETIC TRANSCRIPTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; NONHUMAN; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84860480401     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000204     Document Type: Article

References (75)

1. Fojo A, Hamilton TC, Young RC, et al: Multidrug resistance in ovarian cancer. Cancer 1987; 60(8 suppl): 2075-2080.
2. Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010; 46: 308-316.
3. Sandor V, Fojo T, Bates SE: Future perspectives for the development of P-glycoprotein modulators. Drug Resist Updat 1998; 1: 190-200.
4. Nakagami H, Soukupová H, Schikora A, et al: A Mitogen-activated protein kinase kinase kinase mediates reactive oxygen species homeostasis in Arabidopsis. J Biol Chem 2006; 281: 38697-38704.
5. Kisucká J, Barancík M, Bohácová V, et al: Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells. Gen Physiol Biophys 2001; 20: 439-444.
6. Duraj J, Zazrivcova K, Bodo J, et al: Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma 2005; 52: 273-279.
7. Wei N, Sun H, Wang F, et al: H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein. Cancer Chemother Pharmacol 2011; 67: 1017-1025.
8. Hung CC, Liou HH: YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. Invest New Drugs 2011; 29: 1337-1346.
9. Weston CR, Davis RJ: The JNK signal transduction pathway. Curr Opin Genet Dev 2002; 12: 14-21.
10. Lagadinou ED, Ziros PG, Tsopra OA, et al: c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia. Leukemia 2008; 22: 1899-1908.
11. Zhang Y, Zhou J, Xu W, et al: JWA sensitizes P-glycoprotein-mediated drug-resistant choriocarcinoma cells to etoposide via JNK and mitochondrial-associated signal pathway. J Toxicol Environ Health A 2009; 72: 774-781.
12. Bark H, Choi CH: PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κB. Cancer Chemother Pharmacol 2010; 65: 1131-1136.
13. Osborn MT, Chambers TC: Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 1996; 271:30950-30955.
14. Comerford KM, Cummins EP, Taylor CT: c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1a-dependent P-glycoprotein expression in hypoxia. Cancer Res 2004; 64:9057-9061.
15. Sui H, Zhou S, Wang Y, et al: COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis 2011; 32:667-675.
16. Han J, Lee JD, Bibbs L, et al: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265: 808-811.
17. Barancík M, Bohácová V, Kvackajová J, et al: SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 2001; 14: 29-36.
18. Li Y, Li S, Han Y, et al: Calebin-A induces apoptosis and modulates MAPK family activity in drug resistant human gastric cancer cells. Eur J Pharmacol 2008; 591: 252-258.
19. Jiao JW, Wen F: Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Oncol Rep 2011; 25: 781-788.
20. Ling X, He X, Apontes P, et al: Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin. Am J Transl Res 2009; 1: 393-405.
21. Rohlff C, Glazer RI: Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Cell Signal 1995; 7: 431-443.
22. Ziemann C, Riecke A, Rüdell G, et al: The role of prostaglandin E receptor-dependent signaling via cAMP in Mdr1b gene activation in primary rat hepatocyte cultures. J Pharmacol Exp Ther 2006; 317: 378-386.
23. Pacold ME, Suire S, Perisic O, et al: Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase y. Cell 2000; 103: 931-943.
24. Kuo MT, Liu Z, Wei Y, et al: Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kB signaling. Oncogene 2002; 21: 1945-1954.
25. McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249-279.
26. Wang Y, Qu Y, Niu XL, et al: Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 2011; 56: 365-375.
27. Kaszubiak A, Kupstat A, Müller U, et al: Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1. Biochem Biophys Res Commun 2007; 357: 295-301.
28. Oda Y, Kohashi K, Yamamoto H, et al: Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma. Cancer Sci 2008; 99: 726-732.
29. Keniry M, Parsons R: The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008; 27: 5477-5485.
30. Maehama T, Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13375-13378.
31. Lee S, Choi EJ, Jin C, et al: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 2005; 97: 26-34.
32. Ji D, Deeds SL, Weinstein EJ: A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity. Oncol Rep 2007; 18: 1499-1505.
33. Safe S, Abdelrahim M: Sp transcription factor family and its role in cancer. Eur J Cancer 2005; 41: 2438-2448.
34. Oka M, Kounoura K, Narasaki F, et al: P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. Jpn J Cancer Res 1997; 88: 738-742.
35. Matsuhashi N, Saio M, Matsuo A, et al: The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs. Oncol Rep 2005; 14: 609-615.
36. Rimler A, Jockers R, Lupowitz Z, et al: Differential effects of melatonin and its downstream effector PKCα on subcellular localization of RGS proteins. J Pineal Res 2006; 40: 144-152.
37. Fine RL, Patel J, Chabner BA: Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 1988; 85: 582-586.
38. Blobe GC, Sachs CW, Khan WA, et al: Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC α. J Biol Chem 1993; 268: 658-664.
39. Gekeler V, Boer R, Ise W, et al: The specific bisindolylmaleimide PKC-inhibitor GF 109203X efficiently modulates MRP-associated multiple drug resistance. Biochem Biophys Res Commun 1995; 206: 119-126.
40. Bergman PJ, Gravitt KR, Ward NE, et al: Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-α (PKC-α) pseudosubstrate peptides through a P-glycoprotein-independent mechanism. Invest New Drugs 1997; 15: 311-318.
41. Brügger D, Brischwein K, Liu C, et al: Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations. Anticancer Res 2002; 22: 4229-4232.
42. Zhang H, Jiang H, Sun F, et al: Rapid diagnosis of multidrug resistance in cancer by electrochemical sensor based on carbon nanotubes-drug supramolecular nano -composites. Biosens Bioelectron 2011; 26: 3361-3366.
43. Ozben T: Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006; 580: 2903-2909.
44. Ambudkar SV, Dey S, Hrycyna CA, et al: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398.
45. Stavrovskaya AA: Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000; 65: 95-106.
46. Gillet JP, Efferth T, Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007; 1775: 237-262.
47. Dean M, Rzhetsky A, Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11: 1156-1166.
48. Childs S, Ling V: The MDR superfamily of genes and its biological implications. In: Important Advances in Oncology (DeVita VT, Hellman S, Rosenberg SA, eds). Philadelphia: Lippincott, 1994; pp 21-36.
49. de Vries EF, Doorduin J, Vellinga NA, et al: Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study. Nucl Med Biol 2008; 35: 459-466.
50. Cordon-Cardo C, O'Brien JP, Boccia J, et al: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277-1287.
51. Klappe K, Hummel I, Hoekstra D, et al: Lipid dependence of ABC transporter localization and function. Chem Phys Lipids 2009; 161: 57-64.
52. Chen CJ, Chin JE, Ueda K, et al: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381-389.
53. Vasconcelos FC, Silva KL, Souza PS, et al: Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom 2011; 80: 158-166.
54. Cizmarikova M, Wagnerova M, Schonova L, et al: MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 2010; 10: 62-69.
55. Miltenberger RJ, Farnham PJ, Smith DE, et al: v-Raf activates transcription of growth-responsive promoters via GC-rich sequences that bind the transcription factor Sp1. Cell Growth Differ 1995; 6: 549-556.
56. Kim SH, Lee SH, Kwak NH, et al: Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett 1996; 98: 199-205.
57. Merkle D, Hoffmann R: Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. Cell Signal 2011; 23: 507-515.
58. Misra UK, Pizzo SV: Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades. J Cell Biochem 2009; 108: 998-1011.
59. Leone V, di Palma A, Ricchi P, et al: PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and cAMP-dependent kinase A activation. Am J Physiol Gastrointest Liver Physiol 2007; 293: G673-G681.
60. Wong KK, Engelman JA, Cantley LC: Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010; 20: 87-90.
61. Kikkawa U, Ase K, Ogita K, et al: The role of protein kinase C in cell surface signal transduction and tumor promotion. Gan To Kagaku Ryoho 1986; 13: 861-869 [in Japanese, English abstract].
62. Melisi D, Chiao PJ: NF-κB as a target for cancer therapy. Expert Opin Ther Targets 2007; 11: 133-144.
63. Hien TT, Kim HG, Han EH, et al: Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-κB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res 2010; 54: 918-928.
64. Zhou G, Kuo MT: NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem 1997; 272: 15174-15183.
65. Ogretmen B, Safa AR: Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-KB/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry 1999; 38: 2189-2199.
66. Wang W, McLeod HL, Cassidy J: Disulfiram-mediated inhibition of NF-kB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003; 104:504-511.
67. Szlosarek PW, Balkwill FR: Tumour necrosis factor a: a potential target for the therapy of solid tumours. Lancet Oncol 2003; 4: 565-573.
68. Sethu S, Melendez AJ: New developments on the TNFa-mediated signalling pathways. Biosci Rep 2011; 31: 63-76.
69. DAlessandro N, Flugy A, Tolomeo M, et al: The apoptotic signaling of TNF-a in multidrug resistant Friend leukemia cells. Anticancer Res 1998; 18: 3065-3072.
70. García MG, Alaniz L, Lopes EC, et al: Inhibition of NF-kB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 2005; 29: 1425-1434.
71. Guttridge DC, Mayo MW, Madrid LV, et al: NF-KB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289: 2363-2366.
72. Uzoh CC, Perks CM, Bahl A, et al: PTEN-mediated pathways and their association with treatment-resistant prostate cancer. BJU Int 2009; 104:556-561.
73. Lee JT Jr, Steelman LS, McCubrey JA: Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 2004; 64: 8397-8404.
74. Kohno K, Tanimura H, Sato S, et al: Cellular control of human multidrug resistance 1 (mdr-1) gene expression in absence and presence of gene amplification in human cancer cells. J Biol Chem 1994; 269: 20503-20508.
75. Yuan H, Young CY, Tian Y, et al: Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells. Mol Cell Biochem 2010; 339: 253-262.